Department of Science for Women and Child Health, University of Florence, Viale Pieraccini 24, 50132 Firenze, Italy.
Vaccine. 2012 Mar 30;30(16):2701-5. doi: 10.1016/j.vaccine.2011.12.008. Epub 2011 Dec 14.
Since the introduction of the 7-valent vaccine, invasive pneumococcal disease have greatly decreased; however, changes in the distribution of pneumococcal serotypes have recently highlighted the need for vaccines with wider coverage. The aim of the work was to assess the potential serotype coverage of three pneumococcal conjugate vaccines (7-, 10- and 13-valent) against bacteremic pneumococcal pneumonia and meningitis/sepsis in Italian children.
We determined pneumococcal serotypes in immunocompetent patients who had been admitted to hospital with suspicion of invasive bacterial disease and had confirmed bacteremic pneumococcal pneumonia or meningitis/sepsis determined by molecular detection of Streptococcus pneumoniae in a normally sterile site. Positive samples were serotyped using Realtime-PCR.
Between April 2008 and March 2011, a total of 144 patients (age median 4.1 years; Interquartile range 1.8-5.6) with pneumococcal meningitis/sepsis (n=43) or pneumonia (n=101) from 83 participating centers located in 19 of 20 Italian regions were serotyped. The 10 most prevalent serotypes were 1 (29.9%), 3 (16.0%), 19A (13.2%), 7F (8.3%), 5 (4.2%), 14 (4.2%), 6A (3.5%), 6B (3.5%), 18C (3.5%), 19F (3.5%). Overall, serotype coverage for PCV-7, -10 and -13 were respectively 19.4%, 61.8% and 94.4% with no statistical difference between pneumonia and meningitis/sepsis. Potential coverage was similar for children 0-2 or 2-5 years of age. Cultures resulted positive in 35/99 (35.4%) samples simultaneously obtained for both culture and RT-PCR.
These findings indicate that increasing the potential serotype coverage by introducing PCV13 in the vaccination schedule for infancy could provide substantial added benefit for protection from pneumococcal pneumonia or meningitis/sepsis in Italy in children below 2 years as well in older children. The importance of molecular methods for diagnosis and serotyping of invasive pneumococcal disease was confirmed.
自 7 价疫苗问世以来,侵袭性肺炎球菌病已大大减少;然而,最近肺炎球菌血清型分布的变化突出表明需要更广泛覆盖的疫苗。本研究旨在评估三种肺炎球菌结合疫苗(7、10 和 13 价)对意大利儿童菌血症性肺炎球菌肺炎和脑膜炎/败血症的潜在血清型覆盖。
我们确定了因疑似侵袭性细菌病而入院且分子检测确定为正常无菌部位的菌血症性肺炎球菌肺炎或脑膜炎/败血症的免疫功能正常的患者的肺炎球菌血清型。阳性样本采用实时 PCR 进行血清型分析。
2008 年 4 月至 2011 年 3 月,共对来自意大利 20 个地区中 19 个地区的 83 个参与中心的 144 名患者(中位年龄 4.1 岁;四分位距 1.8-5.6)进行了血清型分析,这些患者患有肺炎球菌脑膜炎/败血症(n=43)或肺炎(n=101)。10 种最常见的血清型为 1 型(29.9%)、3 型(16.0%)、19A 型(13.2%)、7F 型(8.3%)、5 型(4.2%)、14 型(4.2%)、6A 型(3.5%)、6B 型(3.5%)、18C 型(3.5%)、19F 型(3.5%)。总体而言,PCV-7、-10 和 -13 的血清型覆盖率分别为 19.4%、61.8%和 94.4%,肺炎球菌和脑膜炎/败血症之间无统计学差异。0-2 岁和 2-5 岁儿童的潜在覆盖率相似。同时进行培养和 RT-PCR 的 99 份样本中,35 份(35.4%)培养结果阳性。
这些发现表明,在婴儿免疫接种计划中引入 PCV13 可增加潜在的血清型覆盖范围,从而为意大利 2 岁以下和年龄较大儿童的肺炎球菌肺炎或脑膜炎/败血症提供实质性的额外保护。分子方法在侵袭性肺炎球菌病的诊断和血清分型中的重要性得到了证实。